BR0210976A - Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia - Google Patents

Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Info

Publication number
BR0210976A
BR0210976A BR0210976-0A BR0210976A BR0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A
Authority
BR
Brazil
Prior art keywords
once daily
therapy
carvedilol
daily therapy
pharmaceutical composition
Prior art date
Application number
BR0210976-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dilip Shantilal Shanghvi
R Bala Ramesha Chary
Z Ziauddin Tyebji
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0210976A publication Critical patent/BR0210976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Packaging Frangible Articles (AREA)
BR0210976-0A 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia BR0210976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (cg-RX-API-DMAC7.html) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (1)

Publication Number Publication Date
BR0210976A true BR0210976A (pt) 2004-10-05

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210976-0A BR0210976A (pt) 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Country Status (16)

Country Link
US (1) US20030035836A1 (cg-RX-API-DMAC7.html)
EP (1) EP1395258A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004534031A (cg-RX-API-DMAC7.html)
KR (1) KR20040037026A (cg-RX-API-DMAC7.html)
CN (1) CN1525855A (cg-RX-API-DMAC7.html)
AU (1) AU2002314515B2 (cg-RX-API-DMAC7.html)
BE (1) BE1014328A7 (cg-RX-API-DMAC7.html)
BR (1) BR0210976A (cg-RX-API-DMAC7.html)
CA (1) CA2447005A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400607A3 (cg-RX-API-DMAC7.html)
IN (1) IN191028B (cg-RX-API-DMAC7.html)
MX (1) MXPA03010501A (cg-RX-API-DMAC7.html)
PL (1) PL370589A1 (cg-RX-API-DMAC7.html)
RU (1) RU2003133446A (cg-RX-API-DMAC7.html)
WO (1) WO2002092078A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200309724B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051208A1 (en) 1998-04-03 1999-10-14 Bm Research A/S Controlled release composition
DE60224293T2 (de) * 2001-09-21 2008-12-11 Egalet A/S Feste dispersionen mit kontrollierter freisetzung von carvedilol
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2483054A1 (en) * 2002-04-30 2003-11-13 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
US7268156B2 (en) 2002-06-27 2007-09-11 Sb Pharmco Puerto Rico Inc. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
CA2492084A1 (en) 2002-06-27 2004-01-08 Sb Pharmco Puerto Rico Inc. Carvedilol hydobromide
WO2004041252A1 (en) * 2002-11-08 2004-05-21 Egalet A/S Controlled release carvedilol compositions
AU2003283789A1 (en) * 2002-11-22 2004-06-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-blockers having antioxidant and nitric oxide-donor activity
CA2520312C (en) * 2003-03-26 2013-06-18 Egalet A/S Matrix compositions for controlled delivery of drug substances
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
WO2004093850A1 (en) * 2003-04-24 2004-11-04 Jagotec Ag Tablet with coloured core
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
AU2004279318C1 (en) * 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
EP1691789B1 (en) 2003-11-25 2017-12-20 SmithKline Beecham (Cork) Limited Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1686986A4 (en) 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
EP1750717B1 (en) * 2004-02-11 2017-07-19 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007144785A2 (en) * 2006-03-26 2007-12-21 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
ES2400446T5 (es) 2006-08-03 2017-03-13 Horizon Pharma Ag Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
CA2930487A1 (en) * 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
WO2011102506A1 (ja) * 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
TW201141544A (en) 2010-02-22 2011-12-01 Daiichi Sankyo Co Ltd Oral solid extended release dosage form
NZ704011A (en) 2012-07-06 2016-04-29 Egalet Ltd Abuse deterrent pharmaceutical compositions for controlled release
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6056968A (en) * 1997-03-11 2000-05-02 Darwin Discovery Limited Pharmaceutical drug dosage forms providing different release rates
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
JP2003514019A (ja) * 1999-11-15 2003-04-15 スミスクライン・ビーチャム・コーポレイション カルベジロールメタンスルホン酸塩
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
EP1272180B1 (en) * 2000-04-03 2004-09-29 F. Hoffmann-La Roche Ag Concentrated solutions of carvedilol
JP2004518734A (ja) * 2000-10-24 2004-06-24 スミスクライン・ビーチャム・コーポレイション カルベジロールの新規処方

Also Published As

Publication number Publication date
AU2002314515B2 (en) 2007-08-16
RU2003133446A (ru) 2005-03-10
JP2004534031A (ja) 2004-11-11
HUP0400607A2 (hu) 2004-07-28
MXPA03010501A (es) 2004-03-02
ZA200309724B (en) 2005-05-25
US20030035836A1 (en) 2003-02-20
KR20040037026A (ko) 2004-05-04
CA2447005A1 (en) 2002-11-21
HUP0400607A3 (en) 2005-07-28
CN1525855A (zh) 2004-09-01
BE1014328A7 (fr) 2003-08-05
PL370589A1 (en) 2005-05-30
WO2002092078A1 (en) 2002-11-21
EP1395258A1 (en) 2004-03-10
IN191028B (cg-RX-API-DMAC7.html) 2003-09-13

Similar Documents

Publication Publication Date Title
BR0210976A (pt) Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia
Brahmkshatriya et al. Clinical evaluation of Cissus quadrangularis as osteogenic agent in maxillofacial fracture: A pilot study
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
BR9814378A (pt) Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
KR970061244A (ko) 치매 치료용 약학 조성물
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
BR0309595A (pt) Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
Yoshida Oral device therapy for the upper airway resistance syndrome patient
Rizer et al. Macroglossia: etiologic considerations and management techniques
Du Cayla et al. Long-term effectiveness and side effects of mandibular advancement devices on dental and skeletal parameters
BR0016918A (pt) Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR112019026029A2 (pt) Formulações farmacêuticas orais de remogliflozina
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Kumar et al. Management of postburn perioral contracture using a customized static commissural splint and intralesional injections of triamcinolone
US20030109495A1 (en) Nutraceutical solutions comprising dimethyl sulfoxide
BR9909786A (pt) Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica
Deepika et al. Application of Polyvinyl chloride sheet as delayed surgical obturator in maxillectomy defects secondary to mucormycosis-A case series
BR9916963A (pt) Bupropiona para tratamento de doenças virais
Güvenç et al. Adverse Reaction to Customized Composite Peek Abutment: Case report
Doludeniz et al. Hemimasticatory Spasm: Treatment with Low-Level Laser Therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.